Evidence map›Paper›PMID 28144201›Full record

ArticleMateria socio-medica2016

A Cost-benefit Analysis of a Proposed Immigrant Latent Tuberculosis Infection Screening Program for Cyprus.

Savvas Zannetos, Michael A Talias

Open access · greenAbstract read
In one paragraph

Article in Materia socio-medica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Savvas ZannetosDG European Programmes, Coordination and Development, Nicosia, Cyprus; Department of Healthcare Management, Faculty of Economics and Management, Open University of Cyprus, Nicosia, Cyprus.
Michael A TaliasDepartment of Healthcare Management, Faculty of Economics and Management, Open University of Cyprus, Nicosia, Cyprus.
Open University of Cyprus · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe study explored the potential economic benefit of an expanded screening program of immigrants before entrance to Cyprus as a policy to reduce the overall cost of tuberculosis (TB). Thus, the aim of this study is to study whether screening all immigrants coming from countries (including European Union countries) with high incidence of tuberculosis would be in the economic interest of the Republic of Cyprus or not.

methodsIn order to assess whether it could be economically beneficial for Cyprus to expand the screening checks for TB to all immigrants coming from high prevalence countries, a Cost-Benefit Analysis (CBA) was employed, and the Net Present Value (NPV) of the project was calculated. In order to assess for uncertainty, sensitivity analysis using different scenarios, was conducted.

resultsThe analysis has a fifteen year length of implementation period and the base year (Year 0) was 2011. The NPV was estimated at €3,188,653 which is greater than zero; therefore, the expansion of screening diagnostic tests for TB to European citizens coming from countries with high prevalence of TB will have a significant benefit to the Cypriot economy and society. This result is also supported by the fact that all "what-if scenarios" of the sensitivity analysis yielded a positive NPV.

conclusionOur study concludes that testing all immigrants, including immigrants from high prevalence European countries that are not currently tested for TB, would be a cost-saving strategy to reduce the cost of treating TB in Cyprus.

Indexed as

Cost-Benefit AnalysisCyprusImmigrationScreeningTuberculosis

Identifiers

PMID28144201
PMCPMC5239655
OpenAlexW2562968612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.